Invesco Biotechnology & Genome ETF (PBE) Volatility Skew
Implied volatility skew shows how IV varies across strike prices for a given expiration. Steeper skews indicate higher demand for downside protection relative to upside speculation.
Invesco Biotechnology & Genome ETF (PBE) operates in the Financial Services sector, specifically the Asset Management industry, with a market capitalization near $247.8M, listed on AMEX, carrying a beta of 0.81 to the broader market. The Invesco Biotechnology & Genome ETF (Fund) is based on the Dynamic Biotech & Genome Intellidex Index (Index). public since 2005-06-23.
Snapshot as of May 15, 2026.
- Spot Price
- $81.02
- ATM IV
- 24.0%
- IV Skew 25Δ
- -0.008
- IV Rank
- 31.8%
- IV Percentile
- 50.0%
- Term Structure Slope
- 0.002
As of May 15, 2026, Invesco Biotechnology & Genome ETF (PBE) at-the-money implied volatility is 24.0%. IV rank is 31.8% (where 0% is the 52-week low and 100% is the 52-week high). IV percentile is 50.0%. The 25-delta skew is -0.008: skew is roughly flat across the 25-delta wings. High IV rank typically favors premium-selling strategies; low IV rank favors premium-buying.
PBE Strategy Selection at Current Volatility Levels
For Invesco Biotechnology & Genome ETF options at 24.0% ATM IV, mid-range IV rank (31.8%) is the regime where directional conviction matters more than vol-regime positioning; strategy choice should follow the event calendar and the dealer-positioning view rather than IV rank alone. Pair the vol-rank read with the dealer-gamma view and the upcoming-events calendar to confirm the strategy fits both the structural regime and the path-dependent risk. The variance risk premium - the persistent gap between implied and subsequently realized vol - is positive in equity markets on average; high IV rank typically reflects a stretch where the premium is wider than usual.
Learn how volatility skew is reported and how to read the data →
Frequently asked PBE volatility skew questions
- What is the current PBE ATM implied volatility?
- As of May 15, 2026, Invesco Biotechnology & Genome ETF (PBE) at-the-money implied volatility is 24.0%. IV rank is 31.8% on a 0-100% scale anchored to the 1-year IV range. ATM IV is the volatility input that makes a Black-Scholes-equivalent model reproduce the listed at-the-money option prices.
- Is PBE IV high or low historically?
- IV is near its 1-year median, a regime where strategy choice depends on directional conviction and event calendar rather than vol regime.
- What does PBE volatility skew tell options traders?
- Volatility skew is the pattern by which IV varies across strikes for a given expiration. Invesco Biotechnology & Genome ETF skew is roughly flat across the 25-delta wings. Skew matters for risk-defined strategy selection: when downside puts are rich, put-credit spreads capture more premium; when upside calls are rich, call-credit spreads or covered-call writes harvest more.